2025 Partners
Lead Partner
WuXi XDC
WuXi XDC Cayman Inc. (“WuXi XDC” , stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline.
Senior Partners
Ajinomoto Bio-pharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.
BSP Pharmaceuticals
BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxitc characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.
Merck
Merck is the leading Life Science company, providing solutions to help advance the promise of life saving therapies. Our integrated Millipore® CTDMO Services combines our expertise in contract development, manufacturing, and testing from pre-clinical to commercial to accelerate your milestones and breakthroughs – with one experienced partner. Millipore® CTDMO Services offers 15+ years of leading expertise in the conjugation of drug linkers to monoclonal antibodies (mAbs) and facilities specialized for handling highly potent compounds. With our recent capacity expansion for single nanogram OEL HPAPI manufacturing and, an innovative linker-payload technology portfolio, we are the CDMO partner that ADC customers can trust to take them throughout the drug development journey and to serve their future needs.
Synaffix
Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug
conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business model. Synaffix was fully acquired by Lonza in June 2023. Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic
candidates for their pipelines. Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly
deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.
Partners
Exhibitors
Branding Partner
